Nicollet Investment Management Inc. Sells 18,141 Shares of Novo Nordisk A/S $NVO

Nicollet Investment Management Inc. reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 46.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,572 shares of the company’s stock after selling 18,141 shares during the quarter. Nicollet Investment Management Inc.’s holdings in Novo Nordisk A/S were worth $1,047,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in NVO. Janney Montgomery Scott LLC raised its holdings in Novo Nordisk A/S by 107.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 332,003 shares of the company’s stock worth $16,892,000 after purchasing an additional 172,075 shares in the last quarter. GFS Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $286,000. Deutsche Bank AG increased its position in shares of Novo Nordisk A/S by 290.7% during the fourth quarter. Deutsche Bank AG now owns 501,839 shares of the company’s stock valued at $25,534,000 after buying an additional 373,381 shares during the period. Gordian Capital Singapore Pte Ltd increased its position in shares of Novo Nordisk A/S by 73.1% during the fourth quarter. Gordian Capital Singapore Pte Ltd now owns 22,500 shares of the company’s stock valued at $1,145,000 after buying an additional 9,500 shares during the period. Finally, Claret Asset Management Corp raised its stake in Novo Nordisk A/S by 5.2% in the fourth quarter. Claret Asset Management Corp now owns 152,610 shares of the company’s stock worth $7,765,000 after buying an additional 7,612 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 1.3%

Shares of NYSE NVO opened at $42.73 on Thursday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a 50-day moving average of $41.98 and a 200 day moving average of $46.04. The stock has a market cap of $190.78 billion, a P/E ratio of 10.03, a price-to-earnings-growth ratio of 3.78 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on NVO shares. Wolfe Research began coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating for the company. Nordea Equity Research downgraded Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research report on Tuesday, March 3rd. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Finally, Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported that its Wegovy pill has surpassed 3 million prescriptions, signaling strong early demand for the oral obesity treatment and reinforcing the company’s competitive position versus Eli Lilly in the fast-growing GLP-1 market. Novo Wegovy Pill Tops 3M Prescriptions
• Positive Sentiment: The company also said that more than 80% of Wegovy pill customers have never used a GLP-1 before, which suggests the product is expanding Novo’s addressable market beyond existing obesity-drug users. Novo Nordisk CEO interview on Wegovy pill customers
• Positive Sentiment: Novo Nordisk introduced an updated Rybelsus tablet formulation in Canada, adding a more convenient version of its diabetes GLP-1 drug and supporting the company’s broader cardiometabolic franchise. Novo Nordisk introduces updated Rybelsus tablet formulation in Canada
• Neutral Sentiment: Several articles highlighted Novo Nordisk as a key beneficiary of the GLP-1 boom and as part of healthcare ETF exposure themes, which may keep the stock in focus but do not change fundamentals directly. Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
• Neutral Sentiment: Novo’s CEO reiterated that the company aims to be a “cardiometabolic powerhouse” with a diversified pipeline, reinforcing a long-term growth narrative. Novo Nordisk CEO interview
• Negative Sentiment: Novo Nordisk is also heading to court in South Africa to try to stop sales of unapproved semaglutide copies, underscoring ongoing legal and counterfeit-product risks tied to its blockbuster drugs. Novo Nordisk faces off in court with South African weight-loss drug compounder

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.